IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: STEER, Brian Art Unit: 1652

Serial No.: 10/560,957 Examiner : MEAH, Mohammad Y.

Filed: Apr. 03, 2007 Confirmation No.: 1684

Intl. Date: Jul. 02, 2004

Title : GLUCANASES, NUCLEIC ACIDS ENCODING THEM AND

METHODS FOR MAKING AND USING THEM

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Examiner:

In accordance with 37 CFR § 1.97 and 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08. Only copies of foreign patent and non-patent literature documents are submitted herewith.

The Examiner is requested to make these documents of record, initial and return the Forms PTO/SB/08 to the address below.

USSN 10/560,957 PATENT Page : 2 of 3 Attorney Docket No. D1150-7N

The Information Disclosure Statement is submitted under 37 CFR 1.97(d)(1) and (2), after mailing of a Final Office Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application but before the payment of the issue fee and is accompanied by a statement under 37 CFR 1.97(e)(1) and the fee set forth in § 1.17(p).

Statement under 37 CFR 1.97(e)

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

The information contained in this Information Disclosure Statement under 37 CFR § 1.97 and 1.98 is not to be considered as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

PATENT Attorney Docket No. D1150-7N

The Commissioner is hereby authorized to charge any fees associated with this communication or credit any overpayment to Deposit Account <u>50-0661</u>, referencing docket no. <u>D1150-7N</u>.

Date: February 11, 2011 By: /Lynn M. Linkowski/

USSN 10/560,957

Page : 3 of 3

Lynn M. Linkowski Registration No.: 47320

VERENIUM CORPORATION

(Customer No.: 45975) Intellectual Property Department P.O. Box 910550

San Diego, CA 92191-0550

USA

Phone: 858-431-8586

Email: lynn.linkowski@verenium.com